Critics slam ‘absurd’ plans for an Aussie state to ease drug-driving penalties for medicinal cannabis
The New South Wales government is defending planned reforms that would ease drug-driving penalties for some medicinal cannabis patients, after critics warned the changes could compromise road safety. Legislation due to be debated in the state parliament this week would allow eligible prescription holders to avoid penalties following a first and second positive roadside drug test.
Roads Minister Jenny Aitchison told parliament that roadside testing procedures and impairment laws would remain unchanged, insisting the level of detection would stay the same under the proposed system. The move has drawn criticism, with opponents branding the plan "absurd" and questioning whether it risks putting drug-affected drivers back on the road without adequate safeguards.
- NSW plans to ease drug-driving penalties for medicinal cannabis patients
- Eligible patients could avoid penalties for first two positive roadside tests
- Minister says testing and detection rules stay unchanged; critics call it risky
Both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Advocates for reform argue that current drug-driving laws unfairly penalise medicinal cannabis patients, since roadside tests detect the mere presence of THC rather than actual impairment, meaning a patient could be charged days after last using their prescribed medication even while sober and fully capable of driving safely. They point out that this treats cannabis patients more harshly than people taking other impairing prescription medicines, such as opioids or benzodiazepines, who are only penalised if actually impaired. For many patients, the effective choice becomes forgoing legally prescribed treatment or losing their licence and independence, which they see as a disproportionate and unjust outcome for law-abiding citizens following medical advice.
The case against
Opponents of easing the penalties argue that road safety must take precedence, since cannabis, regardless of its legal or medicinal status, can impair reaction time, coordination and judgement in ways that put the driver and others at serious risk. They contend that, unlike alcohol, there is no reliable, widely available roadside test that measures a driver's actual level of impairment from THC, making it far harder to distinguish a genuinely unimpaired patient from someone unsafe to drive. Given this scientific uncertainty, they worry that softening penalties could weaken deterrence generally, be exploited by non-patients, and send a message that drug-driving is being treated less seriously, at a potential cost to public safety on the roads.